

December 23, 2025

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Stock Exchange Road  
Karachi

**Subject: Corporate Briefing Session of Liven Pharma Limited**

Respected

Please find attached the herewith presentation with respect to the corporate briefing session (CBS) of Liven Pharma Limited to be held on Friday 26<sup>th</sup> December 2025 at 3:30 pm via Zoom video conferencing to brief the analysts/members about the performance of the company

Liven is inviting you to a scheduled Zoom meeting.

Topic: Liven's Corporate Briefing Session December 2025  
Time: Dec 26, 2025 03:30 PM Islamabad, Karachi, Tashkent  
Join Zoom Meeting  
<https://us05web.zoom.us/j/85934377316?pwd=IEBdVa3Y7a0c9RkinFGIsIUW1YWS3S.1>

Meeting ID: 859 3437 7316  
Passcode: 5rMsC7

You may please inform the TRE certificate Holders of the exchange accordingly

Your truly  
For and on behalf of  
Liven Pharma Ltd

  
Muhammad Saeed  
Company Secretary



ToThe  
**General Manager**  
Pakistan Stock Exchange



# Corporate Briefing Session

LIVEN PHARMA LIMITED

DECEMBER  
2025



<b>Profile &amp; Coporate Info</b>	<b>03</b>
<b>BOD &amp; Management</b>	<b>04</b>
<b>Vision and Mission Values</b>	<b>05</b>
<b>Product launch</b>	<b>06</b>
<b>New Development</b>	<b>07</b>
<b>Company growth Dynamics</b>	<b>08</b>
<b>Financial Highlights</b>	<b>09</b>
<b>Coming Brands</b>	<b>10</b>
<b>Future Outlook</b>	<b>11</b>
<b>Thank You</b>	<b>12</b>

# Table of Content

What you will find in this presentation will make you more confident about your company



# Profile & Corporate Info

1. A Public Listed Entity
2. State of The Art Manufacturing Facility
3. 95600 Sqft of Sizeable occupancy of Land
4. 6 Dosage forms
5. More than 100 Products
6. Sharia Compliance Company
7. Actively Present on Global Landscape

Birds Eye view of Profile and Corporate information related to share holding structure and percentage

SHARE HOLDER'S CATEGORY	%age
Sponsors	86.8 %
Individuals	3.53%
Free Float	5%
Physical	4.67%





## Management

- ❖ Pir Muhammad Shah CFO
- ❖ Abdullah Shareef DCFO
- ❖ M. Saeed (ADV) Secretary
  - ❖ Athar Mustafa BUH
  - ❖ Dr. M Ayaz PM
- ❖ Muhammad Umar QCM
  - ❖ Saraan Saeed CPO
  - ❖ Ms. Kinat Jaleel AE


## Governing Committees

### Audit Committee

Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
Mr. Usman Mujib Shami	Member (Non-Executive Director)
Mr. Muhammad Saeed	Secretary

### HR and Remuneration Committee

Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
Ms. Firdous Shakir	Member (Executive Director)
Mr. Muhammad Saeed	Secretary



# BOD and Management

Board, Management and Governing Committees

# Vision & Mission

A Non Commercial True Statement a real depiction of the Plans of the Sponsors, Directors & Management.



## VISION

- To make Liven one of the top Pharmaceutical manufacturing company in Sub-Continent by the end of 2030
- To make Pakistan independent in the field of manufacturing of Active Pharmaceutical Ingredients.
- To put up the most state of the art and advance biological manufacturing unit of South East Asia.
- To Invest in the future

## MISSION

- Be a Hope of patients and Medical Practitioners
- Create a company which can produce wonders in the field of medicine.
- Create a Green Pakistan not only thru its own CSR activities but to encourage others to do the same.
- Become a place of satisfaction for its Investors, Sponsors and most importantly Employees.



**Kotamor Injection**  
 Another psychotropic drug in Liquid injectable dosage form has a market Size of over 2.3 Billion according to IQVI Data of 2024. Currently Liven is the Only company which has an approved quota to Launch this Product at a very Crucial time when this product is totally short in the market



**Napolive Tablet**  
 A market size of over 6.89 Billion, though many major players available in the Market making it tough for the new entrants/launch but Napolive has a unique Edge over its competitors that it is sodium free registration means no to least Risk for the hypertensive patients and patients with heart conditions for pain management

What's

# New & Better

Product Launch, New Development Company Growth Dynamics and Financial Highlights



Commissioning of Automatic Blistering Packing Line Machine  
Liven Pharma Limited has successfully commissioned a new 8 million rupees Blistering Packing Line Machine Imported from china in last fiscal year, which is now commissioned and operating successfully which will not only result in 12-15% increase in production but also efficiency

Commissioning of Automatic Ampoule washing machine  
We have also included to 2 Automatic Machines for ampoule processing i.e. Washing and sterilization and again it will not only increase 20-25% efficiency but will also reduce the breakage in processing and will reduce the production losses. And hence will increase the profitability of the company

What's

# New Development

Product Launch, New Development Company  
Growth Dynamics and Financial Highlights





# Growth Dynamics



## Fresh Capital Infusion:

Liven Pharma is raising **PKR 200 million through a rights issue** of 20 million shares at PKR 10 each.

This represents about **21.5% of its current paid-up capital**, strengthening liquidity and enabling expansion.

## Strategic Use of Funds:

Proceeds earmarked for **working capital and capital expenditure (CAPEX)**.

Investments include a **Dry Powder Injectables division**, procurement of vehicles, and regulatory licensing with the Drug Regulatory Authority of Pakistan (DRAP).

## Product Pipeline Expansion:

Launch of **30 new products on toll manufacturing arrangements**, diversifying portfolio and leveraging external production capacity.

Focus on **injectables and specialized formulations**, aligning with market demand for advanced therapies.

## Marketing & Distribution Push:

Significant investment into **wider-scale marketing campaigns** to strengthen brand visibility.

Expansion of **distribution networks** to penetrate deeper into domestic and regional markets.

Enhanced engagement with healthcare professionals to drive prescription uptake.

## Shareholder Value Creation:

Rights issue structured to allow existing shareholders to maintain proportional ownership (21.496 rights shares for every 100 held).

Improved capital base expected to **boost earnings potential** and long-term shareholder returns.

## Growth Outlook:

Combination of **fresh capital, new product launches, and aggressive marketing** positions Liven Pharma for accelerated growth.

Strategic alignment with Pakistan's growing pharmaceutical demand and regulatory compliance enhances sustainability.

Potential to capture **new therapeutic segments** and expand export opportunities.

**In short:** Liven Pharma is entering a new growth phase by combining a PKR 200 million capital raise with a robust pipeline of 30 new products and a stronger marketing drive. This integrated strategy is designed to scale operations, diversify offerings, and enhance market competitiveness.

# Financial Highlights

For the Year Ended June 30, 2025



Particulars	Standalone
For the year ended June 30, 2025	30 <sup>th</sup> Jun 2025
Sales	127,271,949
Gross Profit	17,958,781
Gross Margin	14.11 %
Operating loss	(490,901,673)
Loss After Tax	(584,459,523)
Loss per share - Basic and diluted	(8.37)



# Coming Brands

We are Expanding in the following segments as well

## Hormonal Drugs

- Estradiol Valerate + Norgestrel 2mg/0.5mg tablet
- Northisterone 5mg tablet
- Dryogesterone 10mg tablet

## Some Advance Formulations

- Esomeprazole + Naproxen
- Aspirin + Vonoprazan
- Rebamide
- Biclutamide
- Sildenafil Citrate
- Ferric Carboxymaltose Complex
- Finerenone

## Peniciline

- Piperacillin + Tazobactam Injection injection
- Co-Amoxiclav injection
- Co-Amoxiclav tablet
- Co-Amoxiclav suspension



How is the

# Future Outlook

Shining, Sparkling, Bright like a morning Sun

Most Fortunate and Blessed

All by the Grace of **Almighty**

## Future Outlook

Liven Pharma Ltd is positioned for accelerated growth through fresh capital infusion, expansion of its product portfolio, and stronger marketing initiatives. The company's focus on innovation, regulatory compliance, and market penetration suggests a trajectory toward becoming a more competitive player in Pakistan's pharmaceutical industry.

### Future Outlook of Liven Pharma Ltd

#### •Capital Strengthening:

- Recent PKR 200 million rights issue boosts liquidity and provides resources for expansion projects.
- Funds directed toward new manufacturing facilities, regulatory licensing, and distribution assets.

#### •Product Pipeline Expansion:

- Launch of 30 new products via toll manufacturing, diversifying therapeutic offerings.
- Emphasis on injectables and specialized formulations, aligning with healthcare demand trends.

#### •Marketing & Distribution:

- Aggressive marketing campaigns to enhance brand recognition.
- Expansion of distribution networks across Pakistan and potential regional markets.

#### •Regulatory & Compliance:

- Strengthened focus on DRAP licensing and approvals, ensuring sustainable growth and credibility.
- Compliance investments improve long-term resilience against regulatory risks.

#### •Industry Positioning:

- Pakistan's pharmaceutical sector is growing steadily, offering opportunities for mid-tier players like Liven Pharma to capture market share.
- Potential to leverage export opportunities in regional markets.

#### •Shareholder Value Creation:

•Rights issue allows existing shareholders to maintain proportional ownership while supporting growth.

•Enhanced earnings potential through new product launches and expanded market presence.

In summary: Liven Pharma's future outlook is defined by financial strengthening, product diversification, and aggressive marketing, positioning it for sustainable growth in Pakistan's evolving pharmaceutical landscape.



# Thank You

Abdullah Sharif



+92-3-111-0-45836



info@liven-pharma.com



www.liven-pharma.com

